Literature DB >> 12814449

Population pharmacokinetics of netilmicin in short-term prophylactic treatment.

Nerea Jauregizar1, Jeff A Wald, Ander Astobieta, Jose M Rodriguez Sasiain, John C Lukas, Rosario Calvo.   

Abstract

AIMS: To characterize the population pharmacokinetics of netilmicin, an aminoglycoside antibiotic, in adult urology patients and to develop a covariate model for improved dose titration.
METHODS: Data from 62 adult patients (55 male, seven female), undergoing urological surgery and treated with netilmicin for short-term prophylaxis, were evaluated retrospectively. The group had (median, range) ages 68, 31-92 years, weights 72, 43-106 kg and heights 167, 148-182 cm. No patient showed renal impairment before netilmicin treatment (serum creatinine </=1.9 mg dl-1). Netilmicin (100 mg) was administered as a maximum of four successive intravenous infusions of 30 min, at 8-h intervals. A total of five blood samples were collected from each patient. Prior to analysis, the dataset was divided into 'index' (n = 44) and 'validation' (n = 18) groups at random. The time courses of netilmicin concentrations from all subjects were analysed using a mixed effects, population, nonlinear modelling package (WinNonMix). For covariate model development, a stepwise procedure was used with backward elimination followed by forward inclusion based on age, sex, weight, height, creatinine clearance and type of surgery. The final covariate model parameters from the index group were used to simulate concentrations in the validation group and the bias and precision were compared with the observations.
RESULTS: A bi-compartmental open model with a proportional residual error best described the data. The population parameters for central and peripheral volumes of distribution were (typical population value [interindividual CV%]) Vc = 14.5 l [56%] and Vp = 10.2 l [not estimated], and the systemic and intercompartmental clearances were CL = 3.9 l h-1[42%] and CLQ = 10.1 l h-1[not estimated], respectively. The final population covariate relationships were based on sex (SEX) and creatinine clearance (CrCL): (Vc, l) = 18.9 - 5.9 x SEX [29%] and (CL, l h-1) = 0.06 x CrCL [33%]. Compared with the observations in the validation group, this model showed a bias (95% confidence interval) of -0.028 (-0.28, 0.25) and precision of 1.22 (0.78, 1.34).
CONCLUSION: Bi-compartmental pharmacokinetic parameters of netilmicin have been estimated from clinical data in urological surgery patients using a population approach. A given single dose results in large variability in plasma concentrations and thus the population covariate final model can be used for direct estimation of initial dosing in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814449      PMCID: PMC1884271          DOI: 10.1046/j.1365-2125.2003.01783.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  41 in total

1.  Short-term antibiotic prophylaxis for the prevention of wound infection and secondary meningitis in acoustic neuroma surgery: a ten-year experience in a regional hospital.

Authors:  E Minola; C Farina; C Zappone; M Arosio; N Lorenzi; A Mazzoni
Journal:  J Chemother       Date:  2000-12       Impact factor: 1.714

2.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

3.  Netilmicin pharmacokinetics after single intravenous doses to elderly male patients.

Authors:  P G Welling; A Baumueller; C C Lau; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

4.  A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy.

Authors:  D R McNamara; A N Nafziger; A M Menhinick; J S Bertino
Journal:  J Clin Pharmacol       Date:  2001-04       Impact factor: 3.126

5.  Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method.

Authors:  J M Tréluyer; Y Merlé; A Semlali; G Pons
Journal:  Clin Pharmacol Ther       Date:  2000-06       Impact factor: 6.875

6.  Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance.

Authors:  S Vozeh; P Spring; M Wenk; F Follath
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

7.  Computer-assisted prescribing of kanamycin for patients with renal insufficiency.

Authors:  G E Mawer; S B Lucas; B R Knowles; R M Stirland
Journal:  Lancet       Date:  1972-01-01       Impact factor: 79.321

8.  Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients.

Authors:  S Chang; R C Li; L S Chan; S Y Wong; M Zhu; A T Chan; K Raymond
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

9.  Pharmacokinetics of netilmicin in the presence of normal or impaired renal function.

Authors:  G Humbert; A Leroy; J P Fillastre; G Oksenhendler
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

10.  Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis.

Authors:  F C Luft; D R Brannon; L L Stropes; R J Costello; R S Sloan; D R Maxwell
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

View more
  2 in total

1.  Individualising netilmicin dosing in neonates.

Authors:  Catherine M T Sherwin; Roland S Broadbent; Natalie J Medlicott; David M Reith
Journal:  Eur J Clin Pharmacol       Date:  2008-08-07       Impact factor: 2.953

2.  Pharmacokinetics of teicoplanin in an ICU population of children and infants.

Authors:  John C Lukas; Georgios Karikas; Maria Gazouli; Panagiotis Kalabalikis; Tasos Hatzis; Panos Macheras
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.